Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
INKT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-1.80
vs -1.80
Q3.23
N/A
-1.50
vs -1.90
Q4.23
N/A
-1.60
vs -2.30
Q1.24
N/A
-1.10
vs -1.70
Q2.24
N/A
-0.70
vs -1.80
Q3.24
N/A
-0.50
vs -1.50
Q4.24
N/A
-0.62
vs -1.60
Q1.25
N/A
-0.70
vs -1.10
Q2.25
N/A
-0.46
vs -0.70
Q3.25
N/A
-0.45
vs -0.50
Sales Growth
YoY
Current
Estimates
Q4.22
+1119%
2.7B vs 221.9M
Q1.23
NA
11.7B vs NA
Q2.23
-100%
NA vs 1.6B
Q3.23
-100%
NA vs 1.6B
Q4.23
-533%
-11708192000.00 vs 2.7B
Q1.24
-100%
NA vs 11.7B
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
+100%
NA vs -11708192000
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
+65%
0.65
vs -36.31
Q3.23
+38%
0.38
vs 0.65
Q4.23
+30%
0.3
vs 0.38
Q1.24
+19%
0.19
vs 0.3
Q2.24
+16%
0.16
vs 0.19
Q3.24
+10%
0.1
vs 0.16
Q4.24
+13%
0.13
vs 0.1
Q1.25
NA
NA
vs 0.13
Institutionnal Ownership
QoQ
Q2.23
42
42
vs 11
282%
Q3.23
35
35
vs 42
-17%
Q4.23
36
36
vs 35
3%
Q1.24
33
33
vs 36
-8%
Q2.24
30
30
vs 33
-9%
Q3.24
26
26
vs 30
-13%
Q4.24
23
23
vs 26
-12%
Q1.25
1
1
vs 23
-96%
globenewswire.com
7 hours ago
seekingalpha.com
11 hours ago
globenewswire.com
12 hours ago
globenewswire.com
13 hours ago
seekingalpha.com
13 hours ago
Forecast
NaN%2026-Revenue
-164%2026-EPS
NaN%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
INKT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
NASDAQ
Unprofitable
Unprofitable
-0.07Â ( -0.96%)
Relative Strenght
16
Volume Buzz
-69%
Earning Acce
No
Dist 52w H.
46%